Effect of first-line endocrine therapy in patients with hormone-sensitive advanced breast cancer: A network meta-analysis
OncoTargets and Therapy May 17, 2018
Zhang T, et al. - Researchers determined the optimal sequence, based on the efficacy, for various first-line endocrine monotherapies or combinations for patients with hormone receptor-positive advanced breast cancer. They analyzed data from randomized controlled trials (RCTs) that assessed the effectiveness of the following treatments as a monotherapy or in combination as the first-line treatment: tamoxifen, anastrozole, letrozole, exemestane, fulvestrant, palbociclib, and ribociclib. This analysis included a total of 16 eligible articles (14 RCTs) involving 6,602 patients treated with 10 different first-line endocrine therapies. By providing a longer progression-free survival/time to progression and a more efficacious objective response rate, palbociclib plus letrozole and ribociclib plus letrozole might be the optimal first-line endocrine therapeutic choices for hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries